随着早期胃癌（EGC）诊疗进展，超级微创手术（SMIS）因其器官保全优势成为治疗新趋势。 然而，如何评估SMIS 对于EGC 的治愈度，一直是临床医生和研究者关注的焦点。 本文旨在探讨早期胃癌SMIS 治愈度（SMIS-Cure）评价体系，并与eCure 分级系统进行对比，分析其临床应用价值。SMIS-Cure 评价体系将治愈度分为A（治愈）、B（临床治愈）和C（手术再评估）三级，基于肿瘤特征及术前多模态影像评估淋巴结转移（LNM）风险，为SMIS 术式选择构建了科学的指导框架。 未来该体系将推动SMIS 标准化及多学科协作发展，助力EGC 治疗平衡根治与功能保留的目标。

Advances in the diagnosis and management of early gastric cancer （EGC） have positioned super minimally invasive surgery （SMIS） as an increasingly preferred therapeutic strategy，owing to its capacity for organ preservation.However，assessing the curability of SMIS in EGC persists as a critical concern for clinicians and researchers.This review aims to explore the SMIS-Cure evaluation system for assessing therapeutic efficacy in EGC，comparing it with the eCure grading system and analyzing its clinical application value.The SMIS-Cure framework stratifies curability into three tiers： Grade A （cure），Grade B（clinical cure），and Grade C（surgical reassessment）.By integrating tumor-specific parameters and preoperative multimodal imaging to stratify lymph node metastasis risk，this system establishes an evidencebased protocol for optimizing SMIS procedural selection.Prospective applications of this framework are anticipated to standardize SMIS practices，foster multidisciplinary collaboration，and ultimately advance EGC treatment paradigms by striking an optimal balance between radical intervention and organ function preservation.